Role of immunostimulatory DNA and TLR9 in gene therapy

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 23, Issue 2, 2006, Pages 89-109

  Yasuda, Kei ^a   Wagner, Hermann ^b   Takakura, Yoshinobu ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

CpG motifs; DNA vaccine; Gene therapy; TLR9

Indexed keywords

BACTERIAL DNA; DEXAMETHASONE; DNA VACCINE; GADOLINIUM CHLORIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPLEX; PLASMID DNA; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; CELL ACTIVATION; DNA SEQUENCE; GENE THERAPY; HUMAN; IMMUNOSTIMULATION; METHYLATION; MOLECULAR RECOGNITION; NONHUMAN; REVIEW;

EID: 33748748906     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v23.i2.10     Document Type: Review

References (80)

1. Tokunaga, T, Yamamoto, H, Shimada, S, Abe, H, Fukuda, T, Fujisawa, Y, Furutani, Y, Yano, O, Kataoka, T, Sudo, T, Makiguchi, N, Suganuma, T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst. 1984;72:955-962.
2. Krieg, AM, Yi, AK, Matson, S, Waldschmidt, TJ, Bishop, GA, Teasdale, R, Koretzky, GA, Klinman, DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546-549.
3. Hemmi, H, Takeuchi, O, Kawai, T, Kaisho, T, Sato, S, Sanjo, H, Matsumoto, M, Hoshino, K, Wagner, H, Takeda, K, Akira, SA. Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
4. Yasuda, K, Ogawa, Y, Yamane, I, Nishikawa, M, Takakura, Y. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J Leukoc Biol. 2005;77:71-79.
5. Yasuda, K, Yu, P, Kirschning, CJ, Schlatter, B, Schmitz, F, Heit, A, Bauer, S, Hochrein, H, Wagner, H. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol. 2005;174:6129-6136.
6. Sakurai, F, Terada, T, Yasuda, K, Yamashita, F, Takakura, Y, Hashida, M. The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes. Gene Ther. 2002;9:1120-1126.
7. Liu, F, Shollenberger, LM, Huang, L. Nonimmunostimulatory nonviral vectors. Faseb J. 2004;18:1779-1781.
8. Alton, EW, Stern, M, Farley, R, Jaffe, A, Chadwick, SL, Phillips, J, Davies, J, Smith, SN, Browning, J, Davies, MG, Hodson, ME, Durham, SR, Li, D, Jeffery, PK, Scallan, M, Balfour, R, Eastman, SJ, Cheng, SH, Smith, AE, Meeker, D, Geddes, DM. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999;353:947-954.
9. Wagner, H. The immunobiology of the TLR9 subfamily. Trends Immunol. 2004;25:381-386.
10. Latz, E, Schoenemeyer, A, Visintin, A, Fitzgerald, KA, Monks, BG, Knetter, CF, Lien, E, Nilsen, NJ, Espevik, T, Golenbock, DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Natl Immunol. 2004;5:190-198.
11. Bauer, S. Toll-erating self DNA. Natl Immunol. 2006;7:13-15.
12. Barton, GM, Kagan, JC, Medzhitov, R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Natl Immunol. 2006;7:49-56. Epub 2005;Dec 2011.
13. Krieg, AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-760.
14. Iwasaki, A, Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Natl Immunol. 2004;5:987-995.
15. Yi, AK, Tuetken, R, Redford, T, Waldschmidt, M, Kirsch, J, Krieg, AM. CpG motifs in bacterial DNA activate leukocytes through the pH- dependent generation of reactive oxygen species. J Immunol 1998;160:4755-4761.
16. Hacker, H, Mischak, H, Miethke, T, Liptay, S, Schmid, R, Sparwasser, T, Heeg, K, Lipford, GB, Wagner, H. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. Embo J 1998;17:6230-6240.
17. Rutz, M, Metzger, J, Gellert, T, Luppa, P, Lipford, GB, Wagner, H, Bauer S Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004;34:2541-2550.
18. Takaoka, A, Yanai, H, Kondo, S, Duncan, G, Negishi, H, Mizutani, T, Kano, S, Honda, K, Ohba, Y, Mak, TW, Taniguchi, T. Integral role of IRF-5 in the gene induction program activated by Toll-like receptors. Nature. 2005;434:243-249.
19. Honda, K, Yanai, H, Mizutani, T, Negishi, H, Shimada, N, Suzuki, N, Ohba, Y, Takaoka, A, Yeh, WC, Taniguchi, T. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA. 2004; 101:15416-15421.
20. Honda, K, Yanai, H, Negishi, H, Asagiri, M, Sato, M, Mizutani, T, Shimada, N, Ohba, Y, Takaoka, A, Yoshida, N, Taniguchi, T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005;434:772-777.
21. Sparwasser, T, Miethke, T, Lipford, G, Erdmann, A, Hacker, H, Heeg, K, Wagner, H. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol 1997; 27:1671-1679.
22. Theofilopoulos, AN, Baccala, R, Beutler, B, Kono, DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005; 23:307-336.
23. Ioannou, Y, Isenberg, DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000; 43:1431-1442.
24. Zhao, H, Hemmi, H, Akira, S, Cheng, SH, Scheule, RK, Yew, NS. Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther. 2004; 9:241-248.
25. Kerkmann, M, Costa, LT, Richter, C, Rothenfusser, S, Battiany, J, Hornung, V, Johnson, J, Englert, S, Ketterer, T, Heckl, W, Thalhammer, S, Endres, S, Hartmann, G. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem. 2005; 280:8086-8093.
26. Honda, K, Ohba, Y, Yanai, H, Negishi, H, Mizutani, T, Takaoka, A, Taya, C, Taniguchi, T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature. 2005; 434:1035-1040.
27. Roberts, TL, Sweet, MJ, Hume, DA, Stacey, KJ. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol. 2005; 174:605-608.
28. Vollmer, J, Weeratna, R, Payette, P, Jurk, M, Schetter, C, Laucht, M, Wader, T, Tluk, S, Liu, M, Davis, HL, Krieg, AM. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004; 34:251-262.
29. Cornelie, S, Hoebeke, J, Schacht, AM, Bertin, B, Vicogne, J, Capron, M, Riveau, G. Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition. J Biol Chem. 2004; 279:15124-15129. Epub 12004 Jan 15120.
30. Yew, NS, Zhao, H, Przybylska, M, Wu, IH, Tousignant, JD, Scheule, RK, Cheng, SH. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther. 2002; 5:731-738.
31. Yasuda, K, Ogawa, Y, Kishimoto, M, Takagi, T, Hashida, M, Takakura, Y. Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochem Biophys Res Commun. 2002; 293:344-348.
32. Jiang, W, Reich IC, Pisetsky, DS. Mechanisms of activation of the RAW264.7 macrophage cell line by transfected mammalian DNA. Cell Immunol. 2004; 229:31-40.
33. Yamane, I, Nishikawa, M, Takakura, Y. Cellular uptake and activation characteristics of naked plasmid DNA and its cationic liposome complex in human macrophages. Int J Pharm. 2005; 7:7.
34. Yasuda, K, Rutz M, Schlatter, B, Metzger, J, Luppa, PB, Schmitz F, Haas, T, Heit, A, Bauer, S, Wagner, H. CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA. Eur J Immunol. ( in press ) 2006; 36:431-436
35. Stacey, KJ, Young, GR, Clark F, Sester, DP, Roberts, TL, Naik S, Sweet MJ, Hume, DA. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol. 2003; 170:3614-3620.
36. Sano, K, Shirota, H, Terui, T, Hattori, T, Tamura, G. Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner. J Immunol. 2003; 170:2367-2373.
37. Vollmer, J, Weeratna, RD, Jurk M, Samulowitz U, McCluskie, MJ, Payette, P, Davis, HL, Schetter, C, Krieg, AM. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunol. 2004; 113:212-223.
38. Zhu, FG, Reich CF, Pisetsky, DS. Effect of cytofectins on the immune response of murine macrophages to mammalian DNA. Immunol. 2003;109:255-262.
39. Tousignant, JD, Zhao, H, Yew, NS, Cheng, SH, Eastman, SJ, Scheule, RK. DNA sequences in cationic lipid:pDNA-mediated systemic toxicities. Hum Gene Ther. 2003; 14:203-214.
40. Spies, B, Hochrein, H, Vabulas, M, Huster, K, Busch DH, Schmitz F, Heit, A, Wagner, H. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol. 2003; 171:5908-5912.
41. Babiuk S, Mookherjee, N, Pontarollo, R, Griebel, P, van Drunen Littel-van den Hurk S, Hecker, R, Babiuk, L. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunol. 2004; 113:114-120.
42. Nagata, S. DNA degradation in development and programmed cell death. Annu Rev Immunol. 2005; 23:853-875.
43. Yoshida, H, Okabe, Y, Kawane, K, Fukuyama, H, Nagata, S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Natl Immunol. 2005; 6:49-56. Epub. 2004 Nov 2028.
44. Okabe, Y, Kawane, K, Akira, S, Taniguchi, T, Nagata, S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med. 2005; 202:1333-1339.
45. Ishii, KJ, Coban, C, Kato, H, Takahashi, K, Torii, Y, Takeshita, F, Ludwig, H, Sutter, G, Suzuki, K, Hemmi, H, Sato, S, Yamamoto, M, Uematsu, S, Kawai, T, Takeuchi, O, Akira, SA. Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Natl Immunol. 2006; 7:40-48. Epub 2005 Nov 2013. Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer.
46. Kawai, T, Takahashi, K, Sato, S, Coban, C, Kumar, H, Kato, H, Ishii, KJ, Takeuchi, O, Akira, S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Natl Immunol. 2005; 6:981-988
47. Seth RB, Sun, L, Ea, CK, Chen, ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell. 2005; 122:669-682.
48. Xu, LG, Wang, YY, Han, KJ, Li, LY, Zhai, Z, Shu, HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell. 2005; 19:727-740.
49. McWhirter, SM, Tenoever, BR, Maniatis, T. Connecting mitochondria and innate immunity. Cell. 2005; 122:645-647.
50. Li, S, Wilkinson, M, Xia, X, David, M, Xu, L, Purkel-Sutton, A, Bhardwaj A. Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol Ther. 2005; 11:112-119.
51. Krug, A, Luker, GD, Barchet, W, Leib DA, Akira, S, Colonna, M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood. 2004; 103:1433-1437.
52. Hochrein, H, Schlatter, B, O'Keeffe, M, Wagner, C, Schmitz F, Schiemann, M, Bauer, S, Suter, M, Wagner, H. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci U S A. 2004; 101:11416-11421.
53. Abe, T, Hemmi, H, Miyamoto, H, Moriishi, K, Tamura, S, Takaku, H, Akira, S, Matsuura, Y. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J Virol. 2005;79:2847-2858.
54. Malmgaard, L, Melchjorsen, J, Bowie, AG, Mogensen, SC, Paludan, SR. Viral activation of macrophages through TLR-dependent and -independent pathways. J Immunol. 2004;173:6890-6898.
55. Zhang, Z. Role of MyD88 signaling pathway in the host immune responses in adenoviral vector-mediated gene therapy. Mol Ther. 2005;11(supplement):S157.
56. Ambegia, E, Ansell, S, Cullis, P, Heyes, J, Palmer, L, MacLachlan, I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta. 2005;1669:155-163.
57. Qin, L, Ding, Y, Pahud, DR, Chang, E, Imperiale, MJ, Bromberg, JS. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997;8:2019-2029.
58. Sellins, K, Fradkin, L, Liggitt, D, Dow, S. Type I Interferons potently suppress gene ex pression following gene delivery using liposome(-)DNA complexes. Mol Ther. 2005;12:451-459.
59. Kobayashi, N, Kuramoto, T, Chen, S, Watanabe, Y, Takakura, Y. Therapeutic effect of intravenous interferon gene delivery with naked plasmid DNA in murine metastasis models. Mol Ther. 2002;6:737-744.
60. Kawano, H, Nishikawa, M, Mitsui, M, Takakura, Y. Enhanced anti-tumor effect of interferon gene transfer by sustained transgene expression using CpG-reduced plasmid DNA. Mol Ther. 2005;11(supplement):S272.
61. Hofman, CR, Dileo, JP, Li, Z, Li, S, Huang, L. Efficient in vivo gene transfer by PCR amplified fragment with reduced inflammatory activity. Gene Ther. 2001;8:71-74.
62. Ogawa, S, Lozach J, Benner, C, Pascual, G, Tangirala, RK, Westin, S, Hoffmann, A, Subramaniam S, David, M, Rosenfeld, MG, Glass, CK. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell. 2005;122:707-721.
63. Krieg, AM, Wu, T, Weeratna, R, Efler, SM, Love-Homan, L, Yang, L, Yi, AK, Short, D, Davis, HL. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A 1998;95:12631-12636.
64. Stunz LL, Lenert, P, Peckham D, Yi, AK, Haxhinasto, S, Chang, M, Krieg, AM, Ashman, RF. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002;32:1212-1222.
65. Duramad, O, Fearon, KL, Chang, B, Chan, JH, Gregorio, J, Coffman, RL, Barrat, FJ. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol. 2005; 174:5193-5200.
66. Lenert, P. Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol. 2005;140:1-10.
67. Lau, CM, Broughton, C, Tabor, AS, Akira, S, Flavell, RA, Mamula, MJ, Christensen, SR, Shlomchik MJ, Viglianti, GA, Rifkin, IR, Marshak-Rothstein, A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005; 202:1171-1177.
68. Vollmer, J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, Akira, S, Kelly, KM, Reeves, WH, Bauer, S, Krieg, AM. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med. 2005;202:1575-1585.
69. Barrat, FJ, Meeker, T, Gregorio, J, Chan, JH, Uematsu, S, Akira, S, Chang, B, Duramad, O, Coffman, RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202:1131-1139.
70. Donnelly, JJ, Wahren, B, Liu, MA. DNA vaccines: progress and challenges. J Immunol. 2005;175:633-639.
71. Tudor, D, Dubuquoy, C, Gaboriau, V, Lefevre, F, Charley, B, Riffault, S. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine. 2005;23:1258-1264.
72. D'Souza, S, Rosseels, V, Denis, O, Tanghe, A, De Smet, N, Jurion, F, Palfliet, K, Castiglioni, N, Vanonckelen, A, Wheeler, C, Huygen, K. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immunol. 2002;70:3681-3688.
73. Fischer, L, Minke, J, Dufay, N, Baudu, P, Audonnet, JC. Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine. 2003;21:4593-4596.
74. Nomura, T, Yasuda, K, Yamada, T, Okamoto, S, Mahato, RI, Watanabe, Y, Takakura, Y, Hashida, M. Gene expression and antitumor effects following direct interferon (IFN)- gamma gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice. Gene Ther 1999;6:121-129.
75. Whitmore, M, Li, S, Huang, L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 1999;6:1867-1875.
76. Dow, SW, Fradkin, LG, Liggitt, DH, Willson, AP, Heath TD, Potter, TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999;163:1552-1561.
77. Sakurai, F, Terada, T, Maruyama, M, Watanabe, Y, Yamashita, F, Takakura, Y, Hashida, M. Therapeutic effect of intravenous delivery of lipoplexes containing, the interferon-beta gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Ther. 2003;10:661-668.
78. Dow, SW, Elmslie, RE, Fradkin, LG, Liggitt, DH, Heath TD, Willson, AP, Potter, TA. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther 1999;10:2961-2972.
79. Assogba, BD, Choi, BH, Rho, HM. Transcriptional activation of the promoter of human cytomegalovirus immediate early gene (CMV-IE) by the hepatitis B viral X protein (HBx) through the NF-kappaB site. Virus Res. 2002;84:171-179.
80. Kuramoto, T, Nishikawa, M, Thanaketpaisarn, O, Okabe, T, Yamashita, F, Hashida, M. Use of lipoplex-induced nuclear factor-kappaB activation to enhance transgene expression by lipoplex in mouse lung. J Gene Med. 2006;8:53-62.